XTL Biopharmaceuticals Ltd ADR Total Assets
XTL Biopharmaceuticals Ltd ADR total assets. Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) holds total assets worth $166.00K USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see XTLB stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of XTL Biopharmaceuticals Ltd ADR (2001–2025)
Total assets of XTL Biopharmaceuticals Ltd ADR from 2001 to 2025. This chart illustrates how XTL Biopharmaceuticals Ltd ADR's total assets have evolved over time, based on quarterly financial data. See XTL Biopharmaceuticals Ltd ADR (XTLB) stock price for real-time trading data and today's change.
XTL Biopharmaceuticals Ltd ADR - Asset Composition Analysis
XTL Biopharmaceuticals Ltd ADR Total Assets Breakdown (December 2025)
XTL Biopharmaceuticals Ltd ADR total assets breakdown as of December 2025. XTL Biopharmaceuticals Ltd ADR's total assets of $166.00K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore XTLB current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XTL Biopharmaceuticals Ltd ADR's current assets represent 100.0% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 45.8% of total assets in 2025, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
XTL Biopharmaceuticals Ltd ADR Competitors by Total Assets
Key competitors of XTL Biopharmaceuticals Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
XTL Biopharmaceuticals Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.40 | 0.61 | 27.61 |
| Quick Ratio | 0.40 | 0.61 | 27.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-254.00K | $-867.00K | $6.68 Million |
XTL Biopharmaceuticals Ltd ADR - Advanced Valuation Insights
This section examines the relationship between XTL Biopharmaceuticals Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 53.01 |
| Asset Growth Rate (YoY) | -98.1% |
| Total Assets | $166.00K |
| Market Capitalization | $8.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values XTL Biopharmaceuticals Ltd ADR's assets at a significant premium (53.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: XTL Biopharmaceuticals Ltd ADR's assets decreased by 98.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for XTL Biopharmaceuticals Ltd ADR (2001–2025)
The table below shows the annual total assets of XTL Biopharmaceuticals Ltd ADR from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $166.00K | -98.06% |
| 2024-12-31 | $8.55 Million | +252.43% |
| 2023-12-31 | $2.43 Million | -42.04% |
| 2022-12-31 | $4.19 Million | -36.75% |
| 2021-12-31 | $6.62 Million | +1.77% |
| 2020-12-31 | $6.50 Million | -9.83% |
| 2019-12-31 | $7.21 Million | -15.90% |
| 2018-12-31 | $8.57 Million | +30.20% |
| 2017-12-31 | $6.59 Million | +118.30% |
| 2016-12-31 | $3.02 Million | -43.32% |
| 2015-12-31 | $5.32 Million | -5.69% |
| 2014-12-31 | $5.64 Million | -29.58% |
| 2013-12-31 | $8.02 Million | -27.70% |
| 2012-12-31 | $11.09 Million | +172.18% |
| 2011-12-31 | $4.07 Million | +7.27% |
| 2010-12-31 | $3.80 Million | +431.05% |
| 2009-12-31 | $715.00K | -79.15% |
| 2008-12-31 | $3.43 Million | -75.72% |
| 2007-12-31 | $14.13 Million | -47.48% |
| 2006-12-31 | $26.90 Million | +77.55% |
| 2005-12-31 | $15.15 Million | -40.87% |
| 2004-12-31 | $25.62 Million | +3.10% |
| 2003-12-31 | $24.85 Million | -35.32% |
| 2002-12-31 | $38.42 Million | -30.27% |
| 2001-12-31 | $55.11 Million | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more